Q BioMed
Announces Strontium89 will be available as of September 2020
through Named Patient Program for Bone Metastases Pain Palliation
in EU and Rest of World
-
Named Patient
Programs will allow Providers to treat patients with bone
metastases pain palliation radiopharmaceutical treatment as of
September, 2020
-
Named Patient
Programs will remain in place until the treatment has been
commercialised
in EU and
ROW, which is expected to be completed in 2021
NEW YORK -- August
11, 2020 -- InvestorsHub NewsWire -- Q
BioMed Inc. (OTCQB:
QBIO), a
commercial stage biotech company, announced today it is launching a
Named Patient Program for its non-opioid bone metastases pain
palliation drug, Strontium89 (Strontium Chloride Sr-89 Injection,
USP). The Named Patient Program will be available to physicians and
patients in the EU and throughout the world, and will be
facilitated by
Caligor
Coghlan Pharma Services (CCPS).
Strontium89 is an
FDA-approved, non-opioid radiopharmaceutical indicated for the
treatment of painful skeletal metastases caused by
cancer, and
is agnostic of the
primary tumor. Common primary tumors that metastasize to the bone
include prostate, breast, lung, as well as others. In several
multicenter, placebo-controlled trials in cancer patients with pain
from bone metastases, pain relief occurred in more patients treated
with a single injection of Strontium89 than in patients treated
with an injection of placebo. Strontium89 is administered
intravenously once every three months and for some patients can
reduce or even eliminate the need for opioid analgesics; pain
relief lasts from 2 - 5 months in most patients.
Use of Strontium89
in patients with evidence of seriously compromised bone marrow from
previous therapy or disease infiltration is not recommended unless
the potential benefit of the treatment outweighs its risks. Bone
marrow toxicity is to be expected, particularly in white blood
cells and platelets. The extent of toxicity is variable but effects are generally
transient. In randomized studies of Strontium89,
the majority
of hematologic toxicity was mild
to moderate (Grade 2 or less) and white blood cell and platelet
counts remained within approximately 70% of pretreatment levels.
For more information including Important Safety Information please
visit the
Strontium89 page on Qbiomed.com.
Over ten million
people around the world suffer from pain associated with metastatic
cancer in the bone and may benefit from Strontium89. For nearly two
years, there has been little to no access to this vital therapy,
after manufacturing ceased in December of 2018. Q BioMed is pleased
that the Named Patient Program will ensure immediate global patient
access to an important therapy for this patient population. In the
meantime, Q BioMed is actively pursuing full regulatory and
marketing approval for Strontium89 in all major markets
worldwide.
Denis Corin, CEO of
Q BioMed, said of the program, "We are very happy that Strontium89
is once again available worldwide, and that physicians have the
ability to prescribe a safe, effective and non-opioid treatment to their
bone metastasis pain patients regardless of their primary tumor
type and notably beyond prostate cancer. We are actively working to
ensure that Strontium89 is accessible to patients everywhere and to
extend its relevance and use thorough additional clinical
study."
Any queries about
the program and availability can be directed to
info@qbiomed.com and
at
https://qbiomed.com/pipeline/sr89.
About Q
BioMed Inc.
Q BioMed Inc is a
biotech acceleration and commercial stage company. Q BioMed is
focused on licensing and acquiring undervalued biomedical assets in
the healthcare sector. Q BioMed is dedicated to
providing these target assets the
strategic resources, developmental support, and expansion capital
needed to ensure they meet their developmental potential, enabling
them to provide products to patients in need.
Please
visit
http://www.QBioMed.com and
sign up for regular updates.
Media Contact Q
BioMed:
Denis
Corin
CEO
Investor
Relations
+1(404)
995-6671
ir@qbiomed.com
About
CCPS
Caligor
Coghlan Pharma
Services is a global company focused on changing the healthcare
paradigm by supporting medical device and pharmaceutical companies
from concept to commercialisation.
Providing bespoke development consulting, regulatory and strategic
services, packaging and labelling for clinical trial and initial
commercial launch, early access and compassionate use programs, and
medication/product management, storage, and logistics for
hospitals, pharmacies and global healthcare systems.
Ensuring patients have access to life enhancing treatments
worldwide.
Forward-Looking
Statements:
This press release
may contain "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Such statements include, but are
not limited to, any statements relating to our growth strategy and
product development programs and any other statements that are not
historical facts. Forward-looking statements are based on
management's current expectations and are subject to risks and
uncertainties that could negatively affect our business, operating
results, financial condition and stock price. Factors that
could cause actual results to differ materially from those
currently anticipated are: risks related to our growth strategy;
risks relating to the results of research and development activities; our
ability to obtain, perform under and maintain financing and
strategic agreements and relationships; uncertainties relating to
preclinical and clinical testing; our dependence on third-party
suppliers; our ability to attract, integrate, and retain key
personnel; the early stage of products under development; our need
for substantial additional funds; government regulation; patent and
intellectual property matters; competition; as well as other risks
described in our SEC filings. We expressly disclaim any obligation
or undertaking to release publicly any updates or revisions to any
forward looking statements contained herein to reflect any change
in our expectations or any changes in events, conditions or
circumstances on which any such statement is based, except as
required by law.
